Krystal Biotech (KRYS) Financial Analysis & Valuation | Quarter Chart

Krystal Biotech (KRYS)

KRYS
Price: $378.15
Fair Value: 🔒
🔒score
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullo... more
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gen... more
Description Shares
Market Cap$11.15BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOKrish S. Krishnan
IPO Date2017-09-20CAGR—
Employees275Websitewww.krystalbio.com
Div. Yield—Payout Ratio—
Buy Back Yield0.12%Total Yield0.12%
KRYS chart loading...
Fundamentals Technicals
Enterprise Value$9.35BP/E Ratio50.55
Forward P/E37.53PEG Ratio0.96
P/S Ratio34.53P/B Ratio11.22
P/CF Ratio57.18P/FCF Ratio60.67
EPS$7.48EPS Growth 1Y79.81%
EPS Growth 3Y—EPS Growth 5Y—
Revenue Growth 1Y25.15%Gross Margin0.93%
Operating Margin0.43%Profit Margin0.54%
ROE0.19%ROA0.16%
ROCE0.14%Current Ratio9.46
Quick Ratio9.06Cash Ratio4.65
Debt/Equity0Interest Coverage—
Altman Z Score57.04Piotroski Score5

View Krystal Biotech financial charts →